MUMBAI: Venus Remedies expands its cancer treatment range in the Asian Commonwealth of Independent States (CIS) region with marketing approval from Ukraine for three anti-cancer drugs including paclitaxel, oxaliplatin and irinotecan. expanded.
The company, which has been present on the Ukrainian market for more than 20 years, has 57 product registrations in Ukraine. Total exports to Ukraine amount to $2.2 million. The company aims to increase this figure by 20% next year by strengthening its product portfolio in Ukraine.
Saransh Chaudhary, President, Global Critical Care, Venus Remedies, said: ”
“This achievement further strengthens our position in the international pharmaceutical market,” said Aditi K Chaudhary, President, International Operations, Venus Remedies.
Continued below
The company is awaiting approval from Ukraine for 10 additional marketing authorization applications. With a population of 46.6 million, Ukraine is one of the largest countries in Europe, making it a potentially lucrative pharmaceutical market.
The company has received marketing approval from Ukraine for paclitaxel in concentrations of 100 mg/16.7 ml, 260 mg/43.3 ml, 300 mg/50 ml, and 30 mg/5 ml. Oxaliplatin in concentrations of 50mg/10ml and 100mg/20ml. Irinotecan at concentrations of 100mg/5ml and 40mg/2ml.
Most Read in the Pharmaceutical Industry
Join a community of over 2 million industry professionals
Subscribe to our newsletter for the latest insights and analysis.
Download the ETHealthworld app
- Get real-time updates
- Save your favorite articles
